Clinical studies with matrix metalloproteinase inhibitors

APMIS

Volumn 107, Issue 1, 1999, Pages 174-180

  Brown, Peter D ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Cancer therapy; Clinical trials; Matrix metalloproteinase; Protease inhibitors

Indexed keywords

BAY 12 9568; CGS 27023A; CIPEMASTAT; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER INVASION; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; METASTASIS INHIBITION; METASTASIS POTENTIAL; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0033034041     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01541.x     Document Type: Review

References (41)

1. 1. Bailar JC, Gornik HL. Cancer undefeated. New Eng J Med 1997;336:1569-74.
2. 2. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
3. 3. Kleiner DE, Stetler-Stevenson WG. Structural biochemistrv and activation of matrix metalloproteinases. Curr Op Cell Biol 1993;5:891-7.
4. 4. Strongin A, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72kDa type IV collagenase. J Biol Chem 1995;270:5331-8.
5. 5. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metallo-proteinases - structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
6. 6. Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Medical Oncology 1997;14:1-10.
7. 7. Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M. Recent advances in matrix metalloproteinase inhibitor research. Drug Dev Today 1996;1:16-26.
8. 8. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor niarimastat in healthy male volunteers. Br J Clin Pharm 1998;45:21-6.
9. 9. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W. Structure determination and analysis of human neutrophil collagenase complexed with a hydoxamate inhibitor. Biochemistry 1995;34:14012-20.
10. 10. Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dental Res 1987;66:1310-4.
11. 11. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJP et al. Conversion of a highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Met 1997;15:184-95.
12. 12. Collier MA, Yuen GJ, Bansal SK, Kolis S, Chew TG, Appelt K, Clendennin NJ. A phase I study of the matrix metalloproteinase (MMP) inhibitor AG3340 given in single doses to healthy volunteers. Proc Am Assoc Cancer Res 1997; 38: abstract #1491,221.
13. 13. Shah A, Sundaresan P, Humphrey R, Heller AH. Comparative pharmacokinetics (PK) of BAY 12-9566, a metalloproteinase (MMP) inhibitor, in healthy volunteers and cancer patients. Proc Am Assoc Cancer Res 1998; 39: abstract #3547,521.
14. 14. Wood ND, Aitken M, Durston S, Harris S, McClelland GR, Sharp S. Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Agents and Actions 1998;49:49-55.
15. 15. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988;48:3307-12.
16. 16. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996;56:2815-22.
17. 17. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-8.
18. 18. Sledge GW, Qulali M, Goulet R, Bone EA, Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Res 1995;87:1546-50.
19. 19. Price A, Raja JB, Rewcastle NB, Yong VW, Zhong QS, Brasher P et al. Marked inhibition of tumour growth in a malignant glioma tumour model by the novel synthetic matrix metalloproteinase inhibitor AG3340. Proc Am Assoc Cancer Res 1998; 39: abstract #2058,301.
20. 20. Shalinsky DR, Brekken J, Robinson SR, Varki NV, Daniels R, Bender S et al. Marked inhibition of the proliferation of human adenocarcinoma colon tumours in vivo by orally administered AG3340, a novel matrix metalloproteinase (MMP) inhibitor. Proc Am Assoc Cancer Res 1998; 39: abstract #2059,302.
21. 21. Santos O, McDermott CD, Daniels RG, Appelt K. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 1997;15:499-508.
22. 22. Johnston MR, Mullen JBM, Pagura M, Appelt K, Shalinsky DR. AG3340, a novel matrix metalloproteinase (MMP) inhibitor, decreases growth and metastases of orthotopic human lung cancer in a nude rat preclinical model system. Proc Am Assoc Cancer Res 1998; 39: abstract #2061,302.
23. 23. Bull C, Flynn C, Eberwein D, Casazza AM, Carter CA, Hibner B. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models. Proc Am Assoc Cancer Res 1998; 39: abstract #2062,302.
24. 24. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown P, Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-8.
25. 25. Hibner B, Card A, Flynn C, Casazza AM, Taraboletti G, Rieppi M, Giavazzi R. BAY 12-9566, a novel biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 1998; 39: abstract #2063,302.
26. 26. Anderson IC, Shipp MA, Docherty AJP, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 1996;56:715-8.
27. 27. Neri A, Goggin B, Kolis S, Brekken J, Khelemskaya N, Gabriel L et al. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumours developing in the lung after Ivtail vein implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 1998; 39: abstract #2060,302.
28. 28. Giavazzi R, Garofalo A, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the anti-tumour activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998;4:985-92.
29. 29. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomised trial. J Clin Oncol 1998;16:1788-94.
30. 30. Galardy RE, Cassabone ME, Giese C, Gilbert JH, Lapierre F, Lopez H et al. Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 1994;732:315-23.
31. 31. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 1995;6:967-74.
32. 32. Rowinsky E, Hammond L, Aylesworth C, Humphrey R, Siu L, Smith L. Prolonged administration of BAY 12-9566, an oral non-peptidic biphenyl matrix metalloproteinase (MMP) inhibitor: a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 1998; 17: abstract #836,216a.
33. 33. Hirte H, Goel R, Major P, Waterfield B, Holohan S, Bennett K, et al. Pharmacokinetics of BAY 12-9566: early results of a Canadian phase I dose escalation study in cancer patients. Proc Am Assoc Cancer Res 1998; 39: abstract #2484,364.
34. 34. Goel R, Hirte H, Shah A, Major P, Waterfield B, Holohan S et al. Phase I study of the matrix metalloproteinase inhibitor Bayer 12-9566. Proc Am Soc Clin Oncol 1998; 17: abstract #840,217a.
35. 35. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4:1101-11.
36. 36. Parsons SL, Watson SA, Griffin NR, Steele RJC. An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann Oncol 1996;7:47.
37. 37. Adams M, Thomas H. A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: abstract #838,217a.
38. 38. Carmichael J, Ledermann J, Woll PJ, Gulliford T, Russell RC. Phase IB study if concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer. Proc Am Soc Clin Oncol 1998; 17: abstract #888,232a.
39. 39. Erlichman C, Adjei A, Alberts S, Sloan J, Goldberg R, Pitot H, Rubin J. Phase I study of BAY 12-9566 a matrix metalloproteinase inhibitor (MMPI). Proc Am Soc Clin Oncol 1998; 17: abstract #837,217a.
40. 40. Gore M, A'Hern R, Stankiewicz M, Slevin M. Tumour marker levels during marimastat therapy. Lancet 1996;348:263-4.
41. 41. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors - present achievements and future prospects. Invest New Drugs 1997;15:175-85.